BioProject

Acquisition of resistance to the PARP inhibitor, Olaparib, constitutes a major challenge for the treatment of advanced prostate cancer. More...

Acquisition of resistance to the PARP inhibitor, Olaparib, constitutes a major challenge for the treatment of advanced prostate cancer. The purpose of this study was to identify molecular targets responsible for the development of acquired Olaparib resistance in advanced prostate cancer. Towards this goal, next-generation sequencing (NGS)-based gene expression profiling (RNA-Sequencing; RNA-Seq) was performed on castration-sensitive prostate cancer (CSPC)/Olaparib-sensitive LNCaP cells, castration-sensitive prostate cancer (CSPC)/Olaparib-resistant LN-OlapR cells, castration-resistant prostate cancer (CSPC)/Olaparib-sensitive C4-2B cells, and castration-resistant prostate cancer (CSPC)/Olaparib-resistant 2B-OlapR cells. Overall design: A total of 4 samples were analyzed in this study. The study focused on castration-sensitive prostate cancer (CSPC) cell line, LNCaP, and the derived Olaparib-resistant cell line, LN-OlapR, and castration-resistant prostate cancer (CRPC) cell line, C4-2B, and the derived Olaparib-resistant cell line, 2B-OlapR. The cells were plated for 48 hours with no selection agent and total RNA was isolated (TRIzol) and then submitted for RNA-sequencing analysis. Less...